{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:50:06Z","timestamp":1772772606018,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:00:00Z","timestamp":1629936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Bone health is compromised in acromegaly resulting in vertebral fractures (VFs), regardless of biochemical remission. Sclerostin is a negative inhibitor of bone formation and is associated with increased fracture risk in the general population. Therefore, we compared sclerostin concentrations between well-controlled acromegaly patients and healthy controls, and assessed its relationship with bone mineral density (BMD), and VFs in acromegaly.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Seventy-nine patients (mean age 58.9\u2009\u00b1\u200911.4 years, 49% women) with controlled acromegaly, and 91 healthy controls (mean age 51.1\u2009\u00b1\u200916.9 years, 59% women) were included. Plasma sclerostin levels (pg\/mL) in patients were measured with an ELISA assay, whereas in controls, serum levels were converted to plasma levels by multiplication with 3.6. In patients, VFs were radiographically assessed, and BMD was assessed using dual X-ray absorptiometry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Median sclerostin concentration in controlled acromegaly patients was significantly lower than in healthy controls (104.5\u2009pg\/mL (range 45.7\u2013234.7\u2009pg\/mL) <jats:italic>vs<\/jats:italic> 140.0\u2009pg\/mL (range 44.8\u2013401.6\u2009pg\/mL), <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Plasma sclerostin levels were not related to age, current growth hormone (GH) or insulin-like factor-1 (IGF-1) levels, gonadal state, treatment modality, remission duration, or BMD, VF presence, severity or progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Patients with long-term controlled acromegaly have lower plasma sclerostin levels than healthy controls, as a reflection of decreased osteocyte activity. Further longitudinal studies are needed to establish the course of sclerostin during different phases of disease and its exact effects in acromegalic osteopathy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-021-02850-7","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T20:02:47Z","timestamp":1630008167000},"page":"228-238","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Low sclerostin levels after long-term remission of acromegaly"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8250-7224","authenticated-orcid":false,"given":"Kim M. J. A.","family":"Claessen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris C. M.","family":"Pelsma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman M.","family":"Kroon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoon H.","family":"van Lierop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nienke R.","family":"Biermasz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha M.","family":"Appelman-Dijkstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,26]]},"reference":[{"issue":"1","key":"2850_CR1","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11102-016-0758-6","volume":"20","author":"G Mazziotti","year":"2017","unstructured":"G. Mazziotti et al. Acromegalic osteopathy. Pituitary 20(1), 63\u201369 (2017)","journal-title":"Pituitary"},{"issue":"12","key":"2850_CR2","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1210\/jc.2013-2695","volume":"98","author":"KM Claessen","year":"2013","unstructured":"K.M. Claessen et al. Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J. Clin. Endocrinol. Metab. 98(12), 4808\u20134815 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"2850_CR3","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11102-019-00991-7","volume":"22","author":"B de Azevedo Oliveira","year":"2019","unstructured":"B. de Azevedo Oliveira et al. The acromegalic spine: fractures, deformities and spinopelvic balance. Pituitary 22(6), 601\u2013606 (2019)","journal-title":"Pituitary"},{"issue":"2","key":"2850_CR4","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1210\/jc.2014-2937","volume":"100","author":"G Mazziotti","year":"2015","unstructured":"G. Mazziotti et al. Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J. Clin. Endocrinol. Metab. 100(2), 384\u2013394 (2015)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2850_CR5","doi-asserted-by":"crossref","unstructured":"I.C.M. Pelsma et al. Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study. Eur. J. Endocrinol. 183(4), 427\u2013437 (2020).","DOI":"10.1530\/EJE-20-0415"},{"issue":"8","key":"2850_CR6","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1210\/jc.2013-1460","volume":"98","author":"G Mazziotti","year":"2013","unstructured":"G. Mazziotti et al. Vertebral fractures in patients with acromegaly: a 3-year prospective study. J. Clin. Endocrinol. Metab. 98(8), 3402\u20133410 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"2850_CR7","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1359\/JBMR.050603","volume":"20","author":"S Bonadonna","year":"2005","unstructured":"S. Bonadonna et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J. Bone Min. Res 20(10), 1837\u20131844 (2005)","journal-title":"J. Bone Min. Res"},{"issue":"9","key":"2850_CR8","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra067395","volume":"357","author":"E Canalis","year":"2007","unstructured":"E. Canalis, A. Giustina, J.P. Bilezikian, Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med. 357(9), 905\u2013916 (2007)","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"2850_CR9","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1210\/jc.2016-3693","volume":"102","author":"T Constantin","year":"2017","unstructured":"T. Constantin et al. Calcium and bone turnover markers in acromegaly: a prospective, controlled study. J. Clin. Endocrinol. Metab. 102(7), 2416\u20132424 (2017)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"2850_CR10","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1210\/er.2007-0036","volume":"29","author":"A Giustina","year":"2008","unstructured":"A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29(5), 535\u2013559 (2008)","journal-title":"Endocr. Rev."},{"issue":"12","key":"2850_CR11","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1210\/jc.2008-0791","volume":"93","author":"G Mazziotti","year":"2008","unstructured":"G. Mazziotti et al. Prevalence of vertebral fractures in men with acromegaly. J. Clin. Endocrinol. Metab. 93(12), 4649\u20134655 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"2850_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1530\/eje.1.01820","volume":"152","author":"NR Biermasz","year":"2005","unstructured":"N.R. Biermasz et al. Long-term maintenance of the anabolic effects of GH on the skeleton in successfully treated patients with acromegaly. Eur. J. Endocrinol. 152(1), 53\u201360 (2005)","journal-title":"Eur. J. Endocrinol."},{"issue":"1","key":"2850_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s00774-005-0649-9","volume":"24","author":"M Bolanowski","year":"2006","unstructured":"M. Bolanowski et al. Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function. J. Bone Min. Metab. 24(1), 72\u201378 (2006)","journal-title":"J. Bone Min. Metab."},{"issue":"6","key":"2850_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1046\/j.1365-2265.2003.01777.x","volume":"58","author":"A Scillitani","year":"2003","unstructured":"A. Scillitani et al. Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clin. Endocrinol. (Oxf.) 58(6), 725\u2013731 (2003)","journal-title":"Clin. Endocrinol. (Oxf.)"},{"issue":"1","key":"2850_CR15","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11102-017-0847-1","volume":"21","author":"L Dalle Carbonare","year":"2018","unstructured":"L. Dalle Carbonare et al. Bone histomorphometry in acromegaly patients with fragility vertebral fractures. Pituitary 21(1), 56\u201364 (2018)","journal-title":"Pituitary"},{"issue":"4","key":"2850_CR16","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1210\/jc.2012-4073","volume":"98","author":"M Madeira","year":"2013","unstructured":"M. Madeira et al. Acromegaly has a negative influence on trabecular bone, but not on cortical bone, as assessed by high-resolution peripheral quantitative computed tomography. J. Clin. Endocrinol. Metab. 98(4), 1734\u20131741 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"2850_CR17","first-page":"lxi","volume":"48","author":"F Roelfsema","year":"1970","unstructured":"F. Roelfsema, J. van der Sluys, D. Smeenk, Quantitation of bone and bone turnover in biopsy specimens from the iliac crest in acromegaly. J. Endocrinol. 48(4), lxi (1970)","journal-title":"J. Endocrinol."},{"issue":"5","key":"2850_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1530\/EJE-17-0468","volume":"177","author":"PPB Silva","year":"2017","unstructured":"P.P.B. Silva et al. Bone microarchitecture and estimated bone strength in men with active acromegaly. Eur. J. Endocrinol. 177(5), 409\u2013420 (2017)","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"2850_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1530\/EJE-16-0808","volume":"176","author":"F Malgo","year":"2017","unstructured":"F. Malgo et al. Bone material strength index as measured by impact microindentation is altered in patients with acromegaly. Eur. J. Endocrinol. 176(3), 339\u2013347 (2017)","journal-title":"Eur. J. Endocrinol."},{"issue":"2","key":"2850_CR20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/EJE-16-0340","volume":"175","author":"K Godang","year":"2016","unstructured":"K. Godang et al. Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. Eur. J. Endocrinol. 175(2), 155\u2013164 (2016)","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"2850_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00198-015-3344-2","volume":"27","author":"AR Hong","year":"2016","unstructured":"A.R. Hong et al. Trabecular bone score as a skeletal fragility index in acromegaly patients. Osteoporos. Int 27(3), 1123\u20131129 (2016)","journal-title":"Osteoporos. Int"},{"key":"2850_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bone.2016.10.007","volume":"96","author":"J Delgado-Calle","year":"2017","unstructured":"J. Delgado-Calle, A.Y. Sato, T. Bellido, Role and mechanism of action of sclerostin in bone. Bone 96, 29\u201337 (2017)","journal-title":"Bone"},{"issue":"2","key":"2850_CR23","doi-asserted-by":"publisher","first-page":"R167","DOI":"10.1530\/JME-18-0176","volume":"62","author":"G Holdsworth","year":"2019","unstructured":"G. Holdsworth, S.J. Roberts, H.Z. Ke, Novel actions of sclerostin on bone. J. Mol. Endocrinol. 62(2), R167\u2013r185 (2019)","journal-title":"J. Mol. Endocrinol."},{"key":"2850_CR24","doi-asserted-by":"publisher","unstructured":"Z. Pekkolay et al. Increased serum sclerostin levels in patients with active acromegaly. J Clin Endocrinol Metab 105 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz254.","DOI":"10.1210\/clinem\/dgz254"},{"key":"2850_CR25","doi-asserted-by":"publisher","unstructured":"P.P.B. Silva et al. Impaired bone microarchitecture in premenopausal women with acromegaly: the possible role of Wnt signaling. J Clin Endocrinol Metab (2021). https:\/\/doi.org\/10.1210\/clinem\/dgz254.","DOI":"10.1210\/clinem\/dgz254"},{"key":"2850_CR26","doi-asserted-by":"crossref","unstructured":"M.M. Uygur et al. Prevalence of vertebral fractures and serum sclerostin levels in acromegaly. Endocrine 73(3), 667\u2013673 (2021).","DOI":"10.1007\/s12020-021-02751-9"},{"issue":"4","key":"2850_CR27","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1530\/EJE-20-0415","volume":"183","author":"ICM Pelsma","year":"2020","unstructured":"I.C.M. Pelsma et al. Progression of vertebral fractures in long-term controlled acromegaly: a 9-year follow-up study. Eur. J. Endocrinol. 183(4), 427\u2013437 (2020)","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"2850_CR28","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/EJE-10-1005","volume":"164","author":"MJ Wassenaar","year":"2011","unstructured":"M.J. Wassenaar et al. High prevalence of vertebral fractures despite normal bone mineral density in patients with long-term controlled acromegaly. Eur. J. Endocrinol. 164(4), 475\u2013483 (2011)","journal-title":"Eur. J. Endocrinol."},{"key":"2850_CR29","unstructured":"CBO, Richtlijn Osteoporose en Fractuurpreventie. https:\/\/wwwvolksgezondheidenzorginfo\/bestanden\/documenten\/cborichtlijn-osteoporose-en-fractuurpreventie-2011. 2011."},{"issue":"5","key":"2850_CR30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1530\/EJE-10-0699","volume":"163","author":"AH van Lierop","year":"2010","unstructured":"A.H. van Lierop et al. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur. J. Endocrinol. 163(5), 833\u2013837 (2010)","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"2850_CR31","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1210\/jc.2003-032041","volume":"89","author":"NR Biermasz","year":"2004","unstructured":"N.R. Biermasz et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J. Clin. Endocrinol. Metab. 89(6), 2789\u20132796 (2004)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"2850_CR32","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1210\/jcem.85.12.7042","volume":"85","author":"NR Biermasz","year":"2000","unstructured":"N.R. Biermasz, H. van Dulken, F. Roelfsema, Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. J. Clin. Endocrinol. Metab. 85(12), 4596\u20134602 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"2850_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cca.2014.01.008","volume":"432","author":"HA Ross","year":"2014","unstructured":"H.A. Ross et al. Harmonization of growth hormone measurement results: the empirical approach. Clin. Chim. Acta 432, 72\u201376 (2014)","journal-title":"Clin. Chim. Acta"},{"issue":"1","key":"2850_CR34","first-page":"45","volume":"44","author":"TJ Cole","year":"1990","unstructured":"T.J. Cole, The LMS method for constructing normalized growth standards. Eur. J. Clin. Nutr. 44(1), 45\u201360 (1990)","journal-title":"Eur. J. Clin. Nutr."},{"issue":"3","key":"2850_CR35","first-page":"166","volume":"50","author":"B Rikken","year":"1998","unstructured":"B. Rikken et al. Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm. Res 50(3), 166\u2013176 (1998)","journal-title":"Horm. Res"},{"issue":"12","key":"2850_CR36","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1002\/jbmr.474","volume":"26","author":"AH van Lierop","year":"2011","unstructured":"A.H. van Lierop et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J. Bone Min. Res 26(12), 2804\u20132811 (2011)","journal-title":"J. Bone Min. Res"},{"key":"2850_CR37","unstructured":"A.H. van Lierop, Measurement of circulating sclerostin. in Sclerostin: a key regulator of bone metabolism (Leiden University, 2013). p. 36\u201344."},{"issue":"9","key":"2850_CR38","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"H.K. Genant et al. Vertebral fracture assessment using a semiquantitative technique. J. Bone Min. Res 8(9), 1137\u20131148 (1993)","journal-title":"J. Bone Min. Res"},{"issue":"12","key":"2850_CR39","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1093\/rheumatology\/38.12.1213","volume":"38","author":"D van Der Heijde","year":"1999","unstructured":"D. van Der Heijde et al. Reading radiographs in chronological order, in pairs or as single films has important implications for the discriminative power of rheumatoid arthritis clinical trials. Rheumatology 38(12), 1213\u20131220 (1999)","journal-title":"Rheumatology"},{"issue":"4","key":"2850_CR40","first-page":"335","volume":"3","author":"HW Minne","year":"1988","unstructured":"H.W. Minne et al. A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone Min. 3(4), 335\u2013349 (1988)","journal-title":"Bone Min."},{"key":"2850_CR41","volume-title":"Assessment of fracture risk and its application to screening for postemenopausal osteoporosis","author":"World Health Organisation.","year":"1994","unstructured":"World Health Organisation. Assessment of fracture risk and its application to screening for postemenopausal osteoporosis. (WHO, Geneva, Switzerland), 1994)"},{"key":"2850_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","volume":"96","author":"AH van Lierop","year":"2017","unstructured":"A.H. van Lierop, N.M. Appelman-Dijkstra, S.E. Papapoulos, Sclerostin deficiency in humans. Bone 96, 51\u201362 (2017)","journal-title":"Bone"},{"key":"2850_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bone.2013.10.019","volume":"59","author":"MM Roforth","year":"2014","unstructured":"M.M. Roforth et al. Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. Bone 59, 1\u20136 (2014)","journal-title":"Bone"},{"issue":"52","key":"2850_CR44","doi-asserted-by":"publisher","first-page":"E11238","DOI":"10.1073\/pnas.1707876115","volume":"114","author":"SP Kim","year":"2017","unstructured":"S.P. Kim et al. Sclerostin influences body composition by regulating catabolic and anabolic metabolism in adipocytes. Proc. Natl. Acad. Sci. USA 114(52), E11238\u2013e11247 (2017)","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"2850_CR45","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1002\/jbmr.1888","volume":"28","author":"P Szulc","year":"2013","unstructured":"P. Szulc et al. Correlates of bone microarchitectural parameters and serum sclerostin levels in men: the STRAMBO study. J. Bone Min. Res 28(8), 1760\u20131770 (2013)","journal-title":"J. Bone Min. Res"},{"issue":"10102","key":"2850_CR46","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"B.L. Langdahl et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390(10102), 1585\u20131594 (2017)","journal-title":"Lancet"},{"issue":"10","key":"2850_CR47","first-page":"e10211","volume":"3","author":"P Geusens","year":"2019","unstructured":"P. Geusens et al. The effect of 1 year of romosozumab on the incidence of clinical vertebral fractures in postmenopausal women with osteoporosis: results from the FRAME study. JBMR 3(10), e10211 (2019)","journal-title":"JBMR"},{"issue":"3","key":"2850_CR48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S8756-3282(96)00365-1","volume":"20","author":"BS Noble","year":"1997","unstructured":"B.S. Noble et al. Identification of apoptotic changes in osteocytes in normal and pathological human bone. Bone 20(3), 273\u2013282 (1997)","journal-title":"Bone"},{"key":"2850_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bone.2016.12.004","volume":"96","author":"MT Drake","year":"2017","unstructured":"M.T. Drake, S. Khosla, Hormonal and systemic regulation of sclerostin. Bone 96, 8\u201317 (2017)","journal-title":"Bone"},{"issue":"10","key":"2850_CR50","doi-asserted-by":"publisher","first-page":"E1953","DOI":"10.1210\/jc.2012-2218","volume":"97","author":"AH van Lierop","year":"2012","unstructured":"A.H. van Lierop et al. Circulating sclerostin levels are decreased in patients with endogenous hypercortisolism and increase after treatment. J. Clin. Endocrinol. Metab. 97(10), E1953\u2013E1957 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"2850_CR51","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/jbmr.4033","volume":"35","author":"LT Braun","year":"2020","unstructured":"L.T. Braun et al. The effect of biochemical remission on bone metabolism in Cushing\u2019s syndrome: a 2-year follow-up study. J. Bone Min. Res 35(9), 1711\u20131717 (2020)","journal-title":"J. Bone Min. Res"},{"issue":"3","key":"2850_CR52","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","volume":"50","author":"D Gatti","year":"2012","unstructured":"D. Gatti et al. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50(3), 739\u2013742 (2012)","journal-title":"Bone"},{"issue":"8","key":"2850_CR53","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1210\/jc.2013-1402","volume":"98","author":"AD Anastasilakis","year":"2013","unstructured":"A.D. Anastasilakis et al. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J. Clin. Endocrinol. Metab. 98(8), 3206\u20133212 (2013)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"2850_CR54","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1359\/jbmr.2000.15.1.60","volume":"15","author":"O Verborgt","year":"2000","unstructured":"O. Verborgt, G.J. Gibson, M.B. Schaffler, Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. J. Bone Min. Res 15(1), 60\u201367 (2000)","journal-title":"J. Bone Min. Res"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02850-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02850-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:28:44Z","timestamp":1675643324000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02850-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,26]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2850"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02850-7","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,26]]},"assertion":[{"value":"4 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients and controls gave written informed consent prior to participation in the studies.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All procedures performed in these studies involving patients and controls were in accordance with the ethical standards of the institutional research committee, and with the 1964 Helsinki Declaration and its later amendments. The studies were approved by the Medical Ethics Committee of the Leiden University Medical Center (LUMC).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}